However, despite recommendations of the National Comprehensive Cancer Network guidelines and clinical evidence from phase II trials that anti-ERBB2 therapies improve disease outcomes in ERBB2-positive mCRC patients, no ERBB2-directed approved therapies for patients with CRC are currently approved for clinical use [8,9,10]. Here, ERBB2 is linked to colorectal carcinoma.